New insights for vaccine development against Clostridium difficile infections

Marjorie Pizarro-Guajardo, Nayaret Chamorro-Veloso, Roberto Mauricio Vidal, Daniel Paredes-Sabja

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

7 Citas (Scopus)

Resumen

Increased antibiotic usage is the main risk factor for gut microbiota dysbiosis. In dysbiosis, there is an increased susceptibility to intestinal pathogens, such as Clostridium difficile infection, the leading cause of hospital-acquired infection worldwide. High-spectrum antibiotics, such as vancomycin or metronidazole, also increases the risk of developing CDI symptoms after the treatment. An impaired immune response could also be responsible for the high incidence of recurrence of CDI (R-CDI), suggesting that immune system stimulation could help eradicate the infection in patients suffering multiple episodes in CDI or prevent the infective course. Here, we discuss novel immunotherapeutic approaches that aid the immune system to target C. difficile and how these can be improved.

Idioma originalInglés
Páginas (desde-hasta)73-79
Número de páginas7
PublicaciónAnaerobe
Volumen58
DOI
EstadoPublicada - 1 ago 2019

Áreas temáticas de ASJC Scopus

  • Microbiología
  • Enfermedades infecciosas

Huella

Profundice en los temas de investigación de 'New insights for vaccine development against Clostridium difficile infections'. En conjunto forman una huella única.

Citar esto